Chennai: Generic variations of GLP-1 medication have seen a surge in adoption since March this 12 months and this together with rising persistent illness incidence, and a wholesome pipeline of recent product launches have helped pharma sector clock double-digit progress previously few months.
After the patent expiry for semaglutide in March 2026, a number of generic GLP-1 choices can be found in India. These generics are 50% to 75% cheaper than branded counterparts like Ozempic and Wegovy.
In accordance with the info of India Rankings, the gross sales worth of generic GLP-1 injectable medication has gone up since their launch in March and has reached Rs 460 million by July. In quantity phrases, it shot to 192,000 items by July.
Ind-Ra believes the July 2026 rebound reaffirms the expansion potential of the GLP-1 market. In July GLP-1 generic section grew 15 per cent month on month in worth and 16 per cent in unit progress. Whereas pricing stress could emerge over time, the class continues to develop with vital headroom for additional penetration.
In the meantime, July 2026 12.1 per cent progress of the pharma sector reinforces a structurally stronger progress trajectory for the Indian pharmaceutical market (IPM), pushed by rising persistent illness incidence, accelerating GLP-1 adoption, and a wholesome pipeline of recent product launches.
Since December 2025, the market has been rising at 10-odd per cent and in June it grew by 13.3 per cent and July 12.1 per cent.
Power therapies proceed to realize market share, whereas main corporations with robust persistent portfolios are pulling forward of the market. The cardiac section grew 14.9% in July 2026, the anti-diabetic section noticed 5.8% worth progress and 11.9% progress led by new product launches.
Ind-Ra expects these traits to maintain trade momentum and help 9%-10% yoy gross sales progress in FY27.
